July 01, 2022
Article
In the phase 1b COSMIC-021 trial, the combination of cabozantinib and atezolizumab showed clinical activity with manageable toxicity across several setting in urothelial carcinoma.
May 16, 2022
Article
The study data strongly support PSA screening, particularly in Black men, for whom there is a paucity of clinical trial evidence, according to lead author Spyridon Basourakos, MD.
May 15, 2022
Article
The OS was significantly longer in the avelumab plus BSC vs BSC alone arm in all randomized patients, as well as in patients with PD-L1-positive tumors.
May 09, 2022
Article
In the DS8201-A-U105 trial, the combination of the antibody-drug conjugate trastuzumab deruxtecan and the immunotherapy nivolumab demonstrated antitumor activity in patients with HER2-expressing urothelial carcinoma.